Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... GAITHERSBURG, Md. , Oct. 20, 2014  GenVec, Inc. ... Zola P. Horovitz , Ph.D., from its board of ... GenVec board in August 2003, and served as its chairman ... also served on the Nominating and Corporate Governance and Audit ... Zola for more than a decade of dedicated service to ...
(Date:10/20/2014)... 20, 2014 Earle Martin ... announced today that Ellen Teplitzky, an experienced attorney ... the pharmaceutical industry, has joined the firm as ... legal services practice. NDA Partners provides legal ... and testimony, to top law firms and their ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... deCODE genetics,(Nasdaq: DCGN ) today announced that it ... presentation at the JPMorgan 26th Annual Healthcare,Conference., The ... 7:30 pm GMT on,Thursday, January 10 at the Westin ... through the Investors page on deCODE,s website, http://www.decode.com, ...
... Faced with modest growth in the,traditional life ... to,opportunities in agricultural, biodefense and molecular diagnostics. ... research and,advisory firm BioInformatics, LLC today released ... preferences of scientists working in,these dynamic markets. ...
... million in ... 2007-, - sNDA submitted for ... showing favorable results - - New proteasome inhibitor, MLN2238, enters development ... 2007 net income financial guidance -, CAMBRIDGE, Mass., Jan. 4 Building ...
Cached Biology Technology:Study Examines Media Preferences of Life Scientists in Applied Markets 2Study Examines Media Preferences of Life Scientists in Applied Markets 3Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 2Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 3Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 4Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 5Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 6Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 7Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 8Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results 9
(Date:10/15/2014)...   Neurotechnology , a provider of high-precision ... the VeriLook Surveillance 3.0 software development kit ... face identification using live video streams from single ... version not only identifies faces in a crowd, ... they are moving through the video frame. It ...
(Date:10/14/2014)... house fly genome for the first time, revealing robust ... that thrives in pathogen-rich dung piles and garbage heaps. ... Genome Biology , will increase understanding of house ... adapt to resist insecticides, which could lead to novel ... and transmit more than 100 human and animal diseases, ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... in the February 15th issue of Genes & Development ... in sperm while they reside in the female reproductive ... of successful fertilization. , It had been believed for ... Gur and Haim Breitbart (Bar-Ilan University, Israel) now show ...
... A version of a gene previously linked to ... regulate impulses, emotional memory and thinking in humans, ... National Institute of Mental Health (NIMH) have found. ... ?especially males ?tended to have relatively smaller emotion-related ...
... lactic acid is poison, a waste product that builds ... reduced performance and pain. , Some 30 years of ... a different story: Lactic acid can be your friend. ... physiologist George Brooks, UC Berkeley professor of integrative biology, ...
Cached Biology News:Aggression-related gene weakens brain's impulse control circuits 2Aggression-related gene weakens brain's impulse control circuits 3Lactic acid not athlete's poison, but an energy source - if you know how to use it 2Lactic acid not athlete's poison, but an energy source - if you know how to use it 3Lactic acid not athlete's poison, but an energy source - if you know how to use it 4
... Performance The TSQ Quantum Ultra defines ... bioanalytical and environmental analysis. It features ... APCI probes, a titanium skimmer with superior ... and sensitivity. Its redesigned ion transfer ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... a tetramethylrhodamine-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
... and Bruker BioSpins Metabolic Profiler is ... and analysis of complex mixtures. It ... optional Avance NMR spectrometer and integrated ... statistical analysis for applications like:,Assessment of ...
Biology Products: